The stock of bioMmune Technologies Inc (CVE:IMU) hit a new 52-week high and has $1.59 target or 189.00% above today’s $0.55 share price. The 9 months bullish chart indicates low risk for the $17.25 million company. The 1-year high was reported on Sep, 13 by Barchart.com. If the $1.59 price target is reached, the company will be worth $32.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 21,850 shares traded hands or 25.14% up from the average. bioMmune Technologies Inc (CVE:IMU) has risen 6.00% since August 14, 2016 and is uptrending. It has underperformed by 10.49% the S&P500.
Biommune Technologies Inc, formerly MC Partners Inc, is a Canada biopharmaceutical company. The company has a market cap of $17.25 million. The Firm is a research and development issuer. It currently has negative earnings. The Firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.